
May 2016: Report on ELZA in “Schweiz am Sonntag”
Report on ELZA and its clinical and research activities on refractive laser surgery, cornea, keratoconus and crosslinking (article in German).

Report on ELZA and its clinical and research activities on refractive laser surgery, cornea, keratoconus and crosslinking (article in German).

The ELZA founder Prof. Farhad Hafezi receives the Gold Medal of SAMIR for his pioneering work on corneal cross-linking.

The ELZA Institute was represented at the 2016 congress of MEACO, the Middle Eastern African Congress of Ophthalmology: the ELZA co-founder Farhad Hafezi gave a total of 8 presentations and chaired several sessions

The PowerList Top 100 list is a list of the 100 most influential personalities in ophthalmology, established by the British magazine “The Ophthalmologist”

ARVO, the Association for Research in Vision and Ophthalmology, is the largest annual meeting of the scientific community in ophthalmology, with more than 11’000 attendants.

ELZA is represented at SAMIR 2016: Prof. Farhad Hafezi gives several lectures and courses on keratoconus management and refractive laser surgery

We are very proud to announce that the founder of the ELZA Institute, Prof. Farhad Hafezi, has been voted onto the PowerList 2016 by his peers, for the second time after 2014

The Roski Eye Institute of USC (University of Southern California) with its new web presence. Farhad Hafezi from the ELZA Institute (Zurich, Switzerland) is part of the research faculty

Interview with Prof. Farhad Hafezi on “Current trends in CXL”

The ELZA member Farhad Hafezi is a member of the scientific committee and the co-organizer of the upcoming CXL Experts Meeting in Zurich on December 2-3, 2016.
Stay informed & get the newsletter
You have successfully joined our subscriber list.
Newsletter abonnieren & informiert bleiben
Sie haben sich erfolgreich in unsere Abonnentenliste eingetragen.
Bitte bestätigen Sie Ihr Abonnement, indem Sie auf den Link in der E-Mail klicken, die wir Ihnen gerade geschickt haben.